LLY

768.85

+0.75%↑

JNJ

176.51

-0.72%↓

ABBV

220.71

+0.68%↑

UNH

341.39

-0.06%↓

AZN

76.89

-1.07%↓

LLY

768.85

+0.75%↑

JNJ

176.51

-0.72%↓

ABBV

220.71

+0.68%↑

UNH

341.39

-0.06%↓

AZN

76.89

-1.07%↓

LLY

768.85

+0.75%↑

JNJ

176.51

-0.72%↓

ABBV

220.71

+0.68%↑

UNH

341.39

-0.06%↓

AZN

76.89

-1.07%↓

LLY

768.85

+0.75%↑

JNJ

176.51

-0.72%↓

ABBV

220.71

+0.68%↑

UNH

341.39

-0.06%↓

AZN

76.89

-1.07%↓

LLY

768.85

+0.75%↑

JNJ

176.51

-0.72%↓

ABBV

220.71

+0.68%↑

UNH

341.39

-0.06%↓

AZN

76.89

-1.07%↓

Search

Harmony Biosciences Holdings Inc

Abrir

SetorSaúde

32.13 -1.56

Visão Geral

Variação de preço das ações

24h

Atual

Mín

31.88

Máximo

32.74

Indicadores-chave

By Trading Economics

Rendimento

-5.8M

40M

Vendas

16M

200M

P/E

Médio do Setor

10.45

35.293

EPS

0.92

Margem de lucro

19.839

Funcionários

268

EBITDA

3M

59M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+57.05% upside

Dividendos

By Dow Jones

Próximos Ganhos

28 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-171M

1.9B

Abertura anterior

33.69

Fecho anterior

32.13

Sentimento de Notícias

By Acuity

20%

80%

37 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Harmony Biosciences Holdings Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de set. de 2025, 23:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 de set. de 2025, 22:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 de set. de 2025, 21:59 UTC

Ganhos

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 de set. de 2025, 23:44 UTC

Conversa de Mercado

Nikkei May Rise as Yen Weakens -- Market Talk

17 de set. de 2025, 23:39 UTC

Conversa de Mercado

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 de set. de 2025, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 de set. de 2025, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 de set. de 2025, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 de set. de 2025, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 de set. de 2025, 22:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 de set. de 2025, 21:00 UTC

Ganhos

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 de set. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

17 de set. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

17 de set. de 2025, 19:59 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de set. de 2025, 19:59 UTC

Conversa de Mercado

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 de set. de 2025, 19:07 UTC

Conversa de Mercado

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 de set. de 2025, 18:43 UTC

Conversa de Mercado

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 de set. de 2025, 18:38 UTC

Conversa de Mercado

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 de set. de 2025, 18:20 UTC

Conversa de Mercado

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 de set. de 2025, 18:18 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de set. de 2025, 18:18 UTC

Conversa de Mercado

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 de set. de 2025, 18:14 UTC

Conversa de Mercado

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 de set. de 2025, 17:59 UTC

Conversa de Mercado

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 de set. de 2025, 17:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 de set. de 2025, 17:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 de set. de 2025, 16:51 UTC

Ganhos

Correct: Exor 1H Net Loss -EUR624M

17 de set. de 2025, 16:34 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de set. de 2025, 16:34 UTC

Conversa de Mercado

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 de set. de 2025, 16:25 UTC

Ganhos

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 de set. de 2025, 16:23 UTC

Ganhos

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Comparação entre Pares

Variação de preço

Harmony Biosciences Holdings Inc Previsão

Preço-alvo

By TipRanks

57.05% parte superior

Previsão para 12 meses

Média 50.71 USD  57.05%

Máximo 70 USD

Mínimo 33 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Harmony Biosciences Holdings Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

7

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

29.8 / N/ASuporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Very Strong Bearish Evidence

Sentimento

By Acuity

37 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
help-icon Live chat